GlassScriptPhysician profile
Cheryl Bansal
NPI 1174790851
$13,900.10
in general payments reported to CMS, 2019-2025
37 companies · $4,764 in 2025
The $4,764 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $1,117 · 2021: $1,324 · 2022: $1,566 · 2023: $1,539 · 2024: $2,018 · 2025: $4,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,732 · Consulting Fee: $3,215 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,732.44 |
| Consulting Fee | $3,215.00 |
| Education | $373.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,765.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $1,106.12 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Novartis Pharmaceuticals Corporation | $1,058.03 | 2019-2025 | |
| Janssen Biotech, INC. | $1,049.95 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $954.50 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $712.97 | 2019-2025 | |
| Dermavant Sciences, INC. | $494.67 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $493.55 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Ucb, INC. | $487.53 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $480.85 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $427.87 | 2021-2025 | Opzelura |
| Abbvie INC. | $387.45 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $354.09 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $343.42 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Epi Health, LLC | $307.65 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $293.26 | 2019-2022 | |
| Pfizer INC. | $276.86 | 2019-2025 | |
| Amgen INC. | $261.42 | 2020-2024 | Otezla |
| Organon LLC | $185.86 | 2025 | Vtama, Nexplanon |
| Dermira, INC. | $166.13 | 2019-2021 | |
| Journey Medical Corporation | $151.23 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.61 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $126.23 | 2019 | |
| Sebela Pharmaceuticals INC. | $124.77 | 2019-2022 | |
| Celgene Corporation | $119.60 | 2019 | |
| Sandoz INC. | $108.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.30 | 2024-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $70.01 | 2023 | |
| Dusa Pharmaceuticals, INC. | $64.60 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $58.10 | 2020-2025 | Clear & Brilliant |
| Lnhc, INC | $44.78 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $22.30 | 2019 | |
| Prugen, INC. Pharmaceuticals | $21.19 | 2019 | |
| Botanix Sb INC | $20.74 | 2025 | Sofdra |
| Allergan, INC. | $17.01 | 2019 | |
| Mission Pharmacal Company | $16.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.